Dexrazoxane protects against myelosuppression from the DNA cleavage-enhancing drugs etoposide and daunorubicin but not doxorubicin

Clinical Cancer Research

Volumn 11, Issue 10, 2005, Pages 3915-3924

  Hofland, Kenneth Francis ^a,b,c   Thougaard, Annemette Vinding ^b,c   Sehested, Maxwell ^b,c   Jensen, Peter Buhl ^a,c  

^a FINSEN LABORATORY   (Denmark)

^b Rigshospitalet   (Denmark)

^c BioAlliance Pharma   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DAUNORUBICIN; DOXORUBICIN; ETOPOSIDE; ICR 187; RAZOXANE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD CELL COUNT; BLOOD TOXICITY; BONE MARROW SUPPRESSION; COLONY FORMING UNIT GM; CONTROLLED STUDY; CYTOTOXICITY; DNA CLEAVAGE; DOSE RESPONSE; DRUG ANTAGONISM; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG SENSITIVITY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; WEIGHT REDUCTION;

ANEMIA; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; CARDIOVASCULAR AGENTS; CELL CULTURE TECHNIQUES; COLONY-FORMING UNITS ASSAY; DAUNORUBICIN; DOXORUBICIN; ETOPOSIDE; FEMALE; LEUKOPENIA; MICE; NEUTROPENIA; RAZOXANE; THROMBOCYTOPENIA;

EID: 18844462177     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-2343     Document Type: Article

References (32)

1. Kellner U, Sehested M, Jensen PB, Gieseler F, Rudolph P. Culprit and victim-DNA topoisomerase II. Lancet Oncol 2002;3:235-43.
2. Meresse P, Dechaux E, Monneret C, Bertounesque E. Etoposide: discovery and medicinal chemistry. Curr Med Chem 2004;11:2443-66.
3. Gewirtz DA. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 1999;57:727-41.
4. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 2004;56:185-229.
5. Nitiss JL, Beck WT. Antitopoisomerase drug action and resistance. Eur J Cancer 1996;32A:958-66.
6. Swain SM, Vici P. The current and future role of dexrazoxane as a cardioprotectant in anthracycline treatment: expert panel review. J Cancer Res Clin Oncol 2004;130:1-7.
7. Schuchter LM, Hensley ML, Meropol NJ, Winer EP. 2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2002;20:2895-903.
8. Hasinoff BB, Hellmann K, Herman EH, Ferrans VJ. Chemical, biological and clinical aspects of dexrazoxane and other bisdioxopiperazines. Curr Med Chem 1998;5:1-28.
9. Hasinoff BB. Chemistry of dexrazoxane and analogues. Semin Oncol 1998;25:3-9.
10. Sehested M, Jensen PB, Sorensen BS, Holm B, Friche E, Demant EJ. Antagonistic effect of the cardioprotector (+)-1,2-bis(3,5-dioxopiperazinyl-1- yl)propane (ICRF-187) on DNA breaks and cytotoxicity induced by the topoisomerase II directed drugs daunorubicin and etoposide (VP-16). Biochem Pharmacol 1993;46:389-93.
11. Sehested M, Jensen PB. Mapping of DNA topoisomerase II poisons (etoposide, clerocidin) and catalytic inhibitors (aclarubicin, ICRF-187) to four distinct steps in the topoisomerase II catalytic cycle. Biochem Pharmacol 1996;51:879-86.
12. Classen S, Olland S, Berger JM. Structure of the topoisomerase II ATPase region and its mechanism of inhibition by the chemotherapeutic agent ICRF-187. Proc Natl Acad Sci U S A 2003;100:10629-34.
13. Holm B, Sehested M, Jensen PB. Improved targeting of brain tumors using dexrazoxane rescue of topoisomerase II combined with supralethal doses of etoposide and teniposide. Clin Cancer Res 1998;4:1367-73.
14. Hainsworth JD, Greco FA. Etoposide: twenty years later. Ann Oncol 1995;6:325-41.
15. Stewart CF, Ratain MJ. Anthracyclines and related compounds. In: DeVita VT, Hellman S, Rosenberg SA, editors. Cancer; principles and practices of oncology. 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2001.
16. Supino R. Influence of ICRF-159 or ICRF-186 on cytotoxicity of daunorubicin and doxorubicin. Tumori 1984;70:121 -6.
17. Giuliani F, Casazza AM, Di Marco A, Savi G. Studies in mice treated with ICRF-159 combined with daunorubicin or doxorubicin. Cancer Treat Rep 1981;65:267-76.
18. Herman EH, El Hage AN, Ferrans VJ, Witiak DT. Reduction by ICRF-187 of acute daunorubicin toxicity in Syrian golden hamsters. Res Commun Chem Pathol Pharmacol 1983;40:217-31.
19. Wang G, Finch MD, Trevan D, Hellmann K. Reduction of daunomycin toxicity by razoxane. Br J Cancer 1981;43:871-7.
20. Swain SM, Whaley FS, Gerber MC, Ewer MS, Bianchine JR, Gams RA. Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy. J Clin Oncol 1997;15:1333-40.
21. Swain SM, Whaley FS, Gerber MC, et al. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J Clin Oncol 1997;15:1318-32.
22. Holm B, Jensen PB, Sehested M. ICRF-187 rescue in etoposide treatment in vivo. A model targeting high-dose topoisomerase II poisons to CNS tumors. Cancer Chemother Pharmacol 1996;38:203-9.
23. Pearlman M, Jendiroba D, Pagliaro L, et al. Dexrazoxane's protection of jejunal crypt cells in the jejunum of C3Hf/Kam mice from doxorubicin-induced toxicity. Cancer Chemother Pharmacol 2003;52:477-81.
24. Langer SW, Sehested M, Jensen PB. Dexrazoxane is a potent and specific inhibitor of anthracycline induced subcutaneous lesions in mice. Ann Oncol 2001;12:405-10.
25. Bielack SS, Erttmann R, Kempf-Bielack B, Winkler K. Impact of scheduling on toxicity and clinical efficacy of doxorubicin: what do we know in the mid-nineties? Eur J Cancer 1996;32A:1652-60.
26. Hochster H, Liebes L, Wadler S, et al. Pharmacokinetics of the cardioprotector ADR-529 (ICRF-187) in escalating doses combined with fixed-dose doxorubicin. J Natl Cancer Inst 1992;84:1725-30.
27. Speyer JL, Green MD, Kramer E, et al. Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer. N Engl J Med 1988;319:745-52.
28. Speyer JL, Green MD, Zeleniuch-Jacquotte A, et al. ICRF-187 permits longer treatment with doxorubicin in women with breast cancer. J Clin Oncol 1992;10:117-27.
29. Lemez P, Maresova J. Efficacy of dexrazoxane as a cardioprotective agent in patients receiving mitoxantrone- and daunorubicin-based chemotherapy. Semin Oncol 1998;25:61-5.
30. Frezard F, Garnier-Suillerot A. Comparison of the binding of anthracycline derivatives to purified DNA and to cell nuclei. Biochim Biophys Acta 1990;1036:121-7.
31. Skovsgaard T. Transport and binding of daunorubicin, adriamycin, and rubidazone in Ehrlich ascites tumour cells. Biochem Pharmacol 1977;26:215-22.
32. Wilstermann AM, Osheroff N. Stabilization of eukaryotic topoisomerase II-DNA cleavage complexes. Curr Top Med Chem 2003;3:321-38.